EnCor Biotechnology

Mouse Monoclonal Antibody to SF3B4 Cat# MCA-3A1

$250.00
Description

      The MCA-3A1 antibody was made against full length recombinant human SF3B4 made in and purified from E. coli. Antibodies to this protein such as MCA-3A1 are excellent markers of nuclei and can be used to monitor the nuclear fraction in biochemical experiments. Since the protein is expressed in quite large amounts and ubiquitously in cells and tissues this antibody may also be used as western blotting standard.

Amount: 100µL of 1mg/mL
Amount: 100µL of 1mg/mL
Immunofluorescent analysis of HeLa cells stained with mouse mAb to splicing factor SF3B4, MCA-3A1, dilution 1:1,000 in red, and costained with chicken pAb to vimentin, CPCA-Vim, dilution 1:10,000, in green. The blue is DAPI staining of nuclear DNA. The MCA-3A1 antibody reveals strong granular staining of the nuclei, while the CPCA-Vim antibody specifically labels cytoplasmic intermediate filaments.
Western blot analysis of different cell lysates, cytosol or nuclear enriched fractions, using mouse mAb to splicing factor SF3B4, MCA-3A1, dilution 1:1,000 in green: [1] protein standard (red), [2] NIH-3T3 cytosolic fraction [3] NIH-3T3 nuclear fraction [4] HeLa cytosolic and [5] HeLa nuclear fractions. Strong single band at 49kDa represents the SF3B4 protein, which is expressed exclusively in the nuclei. The same blot was simultaneously probed with rabbit pAb to GAPDH, RPCA-GAPDH, dilution 1:20,000, in red. The 37kDa band corresponds to the GAPDH protein, detected mainly in the cytosolic fractions of these cells.

Add a short description for this tabbed section

Name: Splicing factor SF3B4, mouse monoclonal, Cat# MCA-3A1
Immunogen: Full length recombinant human SF3B4 expressed in and purified from E. coli.
HGNC Name: SF3B4
UniProt: Q15427
Molecular Weight: 49kDa
Host: Mouse
Isotype: IgG2b
Species Cross-Reactivity: Human, Rat, Mouse
RRID: AB_2572386
Format: Purified antibody at 1mg/mL in 50% PBS, 50% glycerol plus 5mM NaN3
Applications: WB, IF/ICC
Recommended Dilutions: WB: 1:1,000. IF/ICC: 1:1,000. IHC: Not Recommended.
Storage: Store at 4°C for short term, for longer term at -20°C

      Splicing factor SF3B4, also known as SAP49, is a ubiquitously expressed splicing factor found in the nuclei of eukaryotic cells, although it migrates into the cytoplasm of dividing cells. It was originally identified by as the protein most efficiently UV cross-linked to the A, B and C spliceosomal complexes (1). The protein contains two of the highly conserved RRM type RNA recognition motifs, each corresponding to a small ~70 amino acid structure, consisting of 4 β-strands and two α-helices. Proteins containing these proteins are believed to have a role in the regulation of mRNA splicing. The SF3B4 protein runs on SDS-PAGE gels at an apparent molecular weight of 49kDa. This protein is also known as splicing factor 3b, subunit 4, 49kDa SAP49, spliceosome-associated protein U2, Hsh49 and MGC108282. Antibodies to this protein are good markers of nuclei.

      This antibody has been tested on formalin fixed and paraffin embedded samples for IHC, and is not recommended for this purpose.

1. Champion-Arnaud P, Reed R. The prespliceosome components SAP 49 and SAP 145 interact in a complex implicated in tethering U2 snRNP to the branch site. Genes Dev. 8:1974-83 (1994).
2. Das BK, et al. Characterization of a Protein Complex Containing Spliceosomal Proteins SAPs 49, 130, 145, and 155. Mol. Cell Biol. 19:6796–802 (1999).
3. Bernier FP, et al. Haploinsufficiency of SF3B4, a Component of the Pre-mRNA Spliceosomal Complex, Causes Nager Syndrome. Am. J. Hum. Genet. 90:925-33 (2012).
4. Petit F, et al. Nager syndrome: confirmation of SF3B4 haploinsufficiency as the major cause. Clin. Genet. 86:246-51 (2014).
5. Marques F, et al. Altered mRNA Splicing, Chondrocyte Gene Expression and Abnormal Skeletal Development due to SF3B4 Mutations in Rodriguez Acrofacial Dysostosis. PLoS Genet. 12:e1006307 (2016).
6. Shen Q, Nam SW. SF3B4 as an early-stage diagnostic marker and driver of hepatocellular carcinoma BMB Rep. 51:57-58 (2018).

Add a short description for this tabbed section